| BAYER |
BAYER |
90%
|
Three Months Ended March 31, 2026 2025 Bayer (as described in Note 10) * 59.6 % |
| BBOT |
BridgeBio Oncology Therapeutics, Inc. |
72%
|
Reciprocal relationship from BBOT graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from BBOT graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from BBOT g… |
| BBOT |
BridgeBio Oncology Therapeutics, Inc. |
72%
|
quity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company’s ownership of Legacy BBOT’s equity was r… |
| KKR |
KKR & Co. Inc. |
72%
|
Reciprocal relationship from KKR graph: Reciprocal relationship from BBIO graph: oing developments in connection with economic conditions, inflationary pressures, evolving regulatory and policy lands… |
| KKR |
KKR & Co. Inc. |
72%
|
oing developments in connection with economic conditions, inflationary pressures, evolving regulatory and policy landscapes, supply chain issues, our commercialization of Attruby/Beyonttra, and timin… |
| OBDC |
Blue Owl Capital Corporation |
72%
|
Item 1A for further discussion related to our royalty monetization arrangements. The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operat… |
| OBDC |
Blue Owl Capital Corporation |
72%
|
Reciprocal relationship from OBDC graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from BBIO graph: Item 1A for further discussion rela… |
| ALEXION-PHARMACEUTICALS-INC |
ALEXION-PHARMACEUTICALS-INC |
62%
|
nt payment of $ 100.0 million and development and sales milestone payments up to $ 81.4 million. To date, we have received $ 100.0 million relating to the upfront payment. In addition, QED is entitle… |
| ALEXION-PHARMA-INTERNATIONAL-OPERATIONS-LIMITED- |
ALEXION-PHARMA-INTERNATIONAL-OPERATIONS-LIMITED- |
62%
|
nt payment of $ 100.0 million and development and sales milestone payments up to $ 81.4 million. To date, we have received $ 100.0 million relating to the upfront payment. In addition, QED is entitle… |
| A-R-LLC |
A-R-LLC |
62%
|
, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software . This ASU makes targeted … |
| BAYER-AG |
BAYER-AG |
62%
|
(including the Buy-Out Payment and all reimbursable expenses). The Funding Agreement will also terminate upon customary events. Under the Funding Agreement, the Seller Parties are required to comply … |
| BAYER-CONSUMER-CARE-AG |
BAYER-CONSUMER-CARE-AG |
62%
|
(including the Buy-Out Payment and all reimbursable expenses). The Funding Agreement will also terminate upon customary events. Under the Funding Agreement, the Seller Parties are required to comply … |
| BRIDGEBIO-INTERNATIONAL-GMBH |
BRIDGEBIO-INTERNATIONAL-GMBH |
62%
|
Item 1A for further discussion related to our royalty monetization arrangements. The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operat… |
| EIDOS-BRIDGEBIO-INTERNATIONAL-GMBH |
EIDOS-BRIDGEBIO-INTERNATIONAL-GMBH |
62%
|
oing developments in connection with economic conditions, inflationary pressures, evolving regulatory and policy landscapes, supply chain issues, our commercialization of Attruby/Beyonttra, and timin… |
| GONDOLABIO-LLC |
GONDOLABIO-LLC |
62%
|
, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software . This ASU makes targeted … |
| GONDOLABIO-SERVICECO-INC |
GONDOLABIO-SERVICECO-INC |
62%
|
ty ownership in GondolaBio was 45.5 %. As of March 31, 2026, the Company’s equity ownership percentage in GondolaBio was 20.4 %. In August 2024, in conjunction with the Transaction Agreement, the lim… |
| HEALTHCARE-ROYALTY-MANAGEMENT-LLC |
HEALTHCARE-ROYALTY-MANAGEMENT-LLC |
62%
|
Item 1A for further discussion related to our royalty monetization arrangements. The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operat… |
| HELIX-ACQUISITION-CORP |
HELIX-ACQUISITION-CORP |
62%
|
quity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company’s ownership of Legacy BBOT’s equity was r… |
| HELIX-II-MERGER-SUB-INC |
HELIX-II-MERGER-SUB-INC |
62%
|
quity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company’s ownership of Legacy BBOT’s equity was r… |
| KYOWA-KIRIN-CO-LTD |
KYOWA-KIRIN-CO-LTD |
62%
|
ructure starting in the low-thirties percent on net sales by Bayer of acoramidis in the Licensed Territory, subject to reduction under certain circumstances as provided in the Bayer License Agreement… |
| NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-LTD |
NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-LTD |
62%
|
roval of any product candidates we may develop resulting in additional losses and depriving us of potential product revenue. Risks Related to the Novel Nature of our Product Candidates Certain of our… |
| NVTS |
Navitas Semiconductor Corporation |
62%
|
Reciprocal relationship from NVTS graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from NVTS graph: Reciprocal relationship from BBIO graph: roval of any product candidates we … |
| PORTAL-THERAPEUTICS-INC |
PORTAL-THERAPEUTICS-INC |
62%
|
, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software . This ASU makes targeted … |
| QED-THERAPEUTICS-INC |
QED-THERAPEUTICS-INC |
62%
|
oing developments in connection with economic conditions, inflationary pressures, evolving regulatory and policy landscapes, supply chain issues, our commercialization of Attruby/Beyonttra, and timin… |
| U-S-BANK-TRUST-COMPANY |
U-S-BANK-TRUST-COMPANY |
62%
|
quity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company’s ownership of Legacy BBOT’s equity was r… |
| US-LLC |
US-LLC |
62%
|
Item 1A for further discussion related to our royalty monetization arrangements. The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operat… |
